UpDoc Becomes the First FDA-Cleared AI Agent for Direct Care

What happened: On June 25, UpDoc officially launched its clinical platform after receiving clearance from the US Food and Drug Administration, FDA, as the first AI agent to provide direct care, starting with insulin dose management for patients with type 2 diabetes. The cleared architecture is hybrid. A conversational interface powered by language models collects patient data, while a deterministic core makes medication decisions exclusively under protocols set by human doctors. The platform has raised $18 million and is being deployed in hospitals such as Cleveland Clinic.

The lens: The governance and regulation lens: the FDA did not clear an automated doctor. It cleared an architecture that separates flexible conversation from deterministic decision making. This is the regulatory blueprint that drug and digital health authorities in the region are likely to follow. For Gulf hospitals built as digital institutions from the outset, the model is ready for regulatory adoption before technical adoption: flexibility at the interface, rigour in the decision.

Source: Innolitics report on UpDoc's FDA clearance